logo
New WHO report fails to rule out COVID-19 lab leak origin as China continues to impede investigation

New WHO report fails to rule out COVID-19 lab leak origin as China continues to impede investigation

Fox News13 hours ago

A World Health Organization (WHO) scientific advisory group on Friday released a report on the origins of COVID-19, concluding that available evidence suggests the deadly pandemic was caused by "zoonotic spillover," either directly from bats or through an intermediate host.
The report from the Scientific Advisory Group for the Origins of Novel Pathogens (SAGO), which claims to be a panel of 27 independent, international, multidisciplinary experts, said that much of the information needed to fully evaluate all hypotheses has not been provided.
However, still citing a believed cause, WHO Director-General Tedros Adhanom Ghebreyesus said that "all hypotheses must remain on the table, including zoonotic spillover and lab leak."
As the Wall Street Journal previously reported, the WHO's COVID-19 origin findings come amid a pattern of suspicious activity.
The WHO traveled to China in early 2021 with British zoologist Dr. Peter Daszak, who was disbarred last year from doing work for the U.S. Department of Health and Human Services and is accused of using American taxpayer dollars to fund gain-of-function research at the bat lab in Wuhan, China.
Once at the Wuhan lab, Daszak and others were allegedly blocked from doing any of the research necessary to investigate.
As noted by the White House when highlighting a report from the Select Subcommittee on the Coronavirus Pandemic, "The Proximal Origin of SARS-CoV-2" publication — which was used repeatedly by public health officials and the media to discredit the lab leak theory — was prompted by Dr. [Anthony] Fauci to push the preferred narrative that COVID-19 originated in nature.
The WHO said it had requested that China share hundreds of genetic sequences from individuals with COVID-19 early in the pandemic, more detailed information about the animals sold at markets in Wuhan, and information on work done and biosafety conditions at laboratories in Wuhan.
To date, China has not shared this information either with SAGO or the WHO.
"I thank each of the 27 members of SAGO for dedicating their time and expertise to this very important scientific undertaking over more than three years," Ghebreyesus wrote in a statement. "… We continue to appeal to China and any other country that has information about the origins of COVID-19 to share that information openly, in the interests of protecting the world from future pandemics."
SAGO published its initial findings and recommendations in a report on June 9, 2022. The most recent report updates the evaluation based on peer-reviewed papers and reviews, as well as available unpublished information and field studies, interviews and other reports, including audit findings, government reports and intelligence reports.
Those part of SAGO convened in various formats 52 times, conducted briefings with researchers, academics, journalists and others, according to the WHO.
"As the report says, this is not solely a scientific endeavor, it is a moral and ethical imperative," Marietjie Venter, chair of the group, wrote in a statement. "Understanding the origins of SARS-CoV-2 and how it sparked a pandemic is needed to help prevent future pandemics, save lives and livelihoods, and reduce global suffering."
"The work to understand the origins of SARS-CoV-2 remains unfinished," the WHO wrote in a statement. "WHO welcomes any further evidence on the origins of COVID-19, and SAGO remains committed to reviewing any new information should it become available."

Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

China Builds Influence in America's Old Pacific Backyard
China Builds Influence in America's Old Pacific Backyard

Bloomberg

time34 minutes ago

  • Bloomberg

China Builds Influence in America's Old Pacific Backyard

'In a desert, an oasis is life saving. And in a vast ocean of blue, a little spot becomes extremely important for survival or defense or power projection,' Cleo Paskal, a senior fellow at the Washington-based think tank Foundation for Defense of Democracies (FDD), explained in a podcast this month. Japan was well aware of this axiom in the early 1900s, when it acquired the administration of a vast stretch of the central Pacific Ocean — offering a series of outposts from which it could cut off its rival, the US, from east Asia. Today, it's China that's eyeing economic and diplomatic inroads into a pivotal area stretching east of the Philippines, from Palau to Micronesia to the Marshall Islands.

Why AstraZeneca risks Trump's wrath with bet on China
Why AstraZeneca risks Trump's wrath with bet on China

Yahoo

time2 hours ago

  • Yahoo

Why AstraZeneca risks Trump's wrath with bet on China

When Pascal Soriot flew in to speak at the Boao Forum in China this year, many expected him to keep a low profile. With Donald Trump and Xi Jinping firing shots at each other in an ever-escalating trade row, it was presumed that the AstraZeneca boss would want to keep his head down. Yet Soriot was happy to make his position clear: 'The two large innovators in our industry today are the US and China,' the no-nonsense Frenchman said on the sidelines of the forum, and China was set to 'emerge as really a driving force for innovation in our sector'. Days later, Soriot was one of 40 Western executives summoned to a gathering with Xi Jinping, orchestrated to cement ties between global corporations and Beijing. 'China is absolutely open for us,' Soriot said. Such statements threaten to thrust AstraZeneca into the spotlight at a time when US and China leaders are painfully sensitive to where companies are spending their cash. In recent months, Trump has sought to exert growing power over where companies are investing. In particular, he is keen to ensure it is not in China. Trump has threatened heavy tariffs on Apple unless it moves its manufacturing out of China and the trade deal with the UK struck earlier this year handed the US a 'veto' over Chinese investment in Britain. While the US president's focus has so far been on pulling manufacturing jobs back to America, many company chiefs are wary of finding themselves in Trump's firing line. For pharmaceutical companies, there are particular risks. Trump this year threatened new tariffs on pharmaceuticals, adding: 'When they hear that, they will leave China.' The US is currently in the middle of an investigation into drug imports, which could be a precursor to action. For AstraZeneca, which does not ship drugs between the US and China, it may seem like they should be immune. Yet Trump's unpredictability means nothing can be assumed – and the president has been clear he wants companies to invest in the US, not China. The president's push to make multinationals choose between the US and China is awkward for AstraZeneca, Britain's biggest pharmaceuticals company. AstraZeneca has been in China for more than 30 years and is the largest drugmaker in the country. It made its first foray into the US in the 1970s and now makes 42pc of its revenues there. Both countries have benefited from recent investment from the British drugmaker. Last November, AstraZeneca put $3.5bn into the US to expand its research and manufacturing facilities. It unveiled a $2.5bn (£2.6bn) new centre in Beijing in March. Two weeks ago, AstraZeneca announced a new strategic partnership with China's CSPC Pharmaceuticals Group, worth up to $5.3bn. Michel Demaré, the company's chairman, insists the business is above the fray. 'When you are a global company like AstraZeneca you have always to cope with geopolitical risk,' he told the Financial Times in 2023. 'You have to try to manage that without getting too involved.' Yet taking a studiously neutral approach is becoming ever more difficult. When it comes to Trump, 'the company will have to manage a tightrope to ensure that they are not going to be penalised for their commitment to China and the wider Asian region,' says Ketan Patel, a fund manager at Whitefriars who is an AstraZeneca investor. Over the past few years Soriot has not been shy in voicing his admiration of China. This year, he said that the nation was paving the way in fast-moving areas including antibody drug conjugates and cell therapy. 'They're very committed to China,' says Emily Field, a Barclays analyst who follows the company. 'And that's because there's going to be this huge volume opportunity where Chinese local players are not able to produce drugs.' Patel believes recent pledges from AstraZeneca to do more research in the country and strike deals with Chinese biotechs are a risk move. 'Research and development is a long duration activity and the current partnerships with local players is very much at a nascent stage.' It is not hard to see why some investors are nervous. This year, more than 100 of AstraZeneca's former sales staff were jailed in China over alleged medical insurance fraud. The National Healthcare Security Administration claimed AstraZeneca staff had been involved in scamming medical insurance companies. At the same time, Chinese authorities have been investigating alleged illegal imports of unapproved medicines. AstraZeneca has said it risks millions of dollars worth of fines. Perhaps most seriously for AstraZeneca is the situation surrounding Leon Wang, its country president in China. He was then detained in China last autumn amid an investigation into AstraZeneca's activities in the country and remains in detention today. AstraZeneca says it has been unable to speak to him. 'We all think [about] and miss Leon,' Soriot said this year. 'We certainly wish him the best and we all hope that he's in good, good shape and dealing with a very difficult situation in the best possible way.' Wang has been put on 'extended leave' and replaced for now. Amnesty International said earlier this year the case raised 'difficult ethical questions' about AstraZeneca staying in China. The drugs giant argues that its role as a manufacturer of medicine means it has a moral right to be in as many countries around the world as it can. It has, for example, kept operating in Russia even as other companies have quit over the war in Ukraine. Still, AstraZeneca is not just remaining in China but ramping up its investments. With Beijing pushing to make the country a better place to create new drugs and run clinical trials, Soriot has hailed the country's pharmaceutical market as 'incredible'. By the end of last year, AstraZeneca had over 200 projects in development in China. The company, which currently has around 40 medicines in China, has around 100 new medicines expected to be approved in China in the next five years. Soriot argues that he has little choice but to turn to China, given ever increasing tax and red tape in Europe make it harder to get things done. In April, Soriot said the continent was 'falling behind in attracting R&D and manufacturing investments, putting its ability to protect the health of its own people at risk'. There is a potential for things to change. This week, UK ministers have been thrashing out plans to try to boost Britain's competitiveness in an effort to attract more life sciences investment from the likes of AstraZeneca. On Thursday, talks were under way to try to come to an agreement on the contentious issue of NHS charges paid by drugmakers. Labour is expected to publish its own overarching life sciences strategy imminently. For now, though, AstraZeneca is focused on China – despite the risks of angering Trump. 'Of course, the US remains extremely important,' Soriot said in April. 'It's the biggest innovation part of the industry. But China is rapidly ramping up and so it's important for us to remain very committed to China.' Broaden your horizons with award-winning British journalism. Try The Telegraph free for 1 month with unlimited access to our award-winning website, exclusive app, money-saving offers and more.

US and China agree framework deal to extend trade war truce
US and China agree framework deal to extend trade war truce

Yahoo

time3 hours ago

  • Yahoo

US and China agree framework deal to extend trade war truce

The US and China have extended the truce in their trade war after two days of talks in London that resulted in a 'framework' deal over export restrictions on rare earths and semiconductors. Negotiations to resolve the wider tariff war triggered by Donald Trump in April will continue but the truce settles, for now, growing tension between the two economic super-powers. The talks, which broke up at about midnight UK time after more than 20 hours of discussions over two days, were led by the Treasury secretary, Scott Bessent, alongside the US commerce secretary, Howard Lutnick, and the trade representative, Jamieson Greer. Lutnick expressed optimism on Tuesday that concerns about critical or rare earth' minerals and magnets, which are vital to a range of industries including cars, electronics and defence, would be resolved as the deal was implemented. The wider dispute, triggered by Trump's decision to impose triple-digit tariffs on Chinese imports in April – since eased to a baseline 30% – has yet to be resolved with China's exports to the US plunging 35% year on year in May. Both sides had accused each other of reneging on a preliminary trade deal struck in Geneva last month to ease retaliatory tariffs, with China putting restrictions on exports of rare earths and the US continuing curbs on semiconductor exports. But the trade war has already caused damage on both sides, whatever the positioning and rhetoric. China's exports to the US plunged 35% year on year in May. The choked global supply of rare earths, which China controls, was already threatening to halt production in the automotive sector this summer on both sides of the Atlantic, with permanent magnets used in everything from windscreen wipers to doors. China's delegation was headed up by the vice-premier He Lifeng – a seasoned negotiator at the top of the Chinese government who had also led talks in Geneva. Lutnick told reporters that Tuesday's framework put 'meat on the bones' of the Geneva deal. Its implementation had faltered over China's curbs on critical mineral exports. The deal also would remove some US export restrictions that were recently put in place, Lutnick said. 'We have reached a framework to implement the Geneva consensus and the call between the two presidents,' Lutnick said. 'The idea is we're going to go back and speak to President Trump and make sure he approves it. They're going to go back and speak to President Xi and make sure he approves it, and if that is approved, we will then implement the framework.' Related: China accuses Pete Hegseth of sowing division in Asia in speech 'filled with provocations' In a separate briefing, China's vice commerce minister Li Chenggang said a trade framework had been reached that would be taken back to US and Chinese leaders. There was a cautious welcome from investors and analysts. 'At least now there's a bottom line that neither side is willing to cross,' said Mark Dong, a co-founder of Minority Asset Management in Hong Kong. Deutsche Bank's note to clients on Wednesday was more sceptical. 'So while the mood music has stayed positive, investors may be wary of the pattern that emerged during the previous US-China trade talks in 2018-19, when apparently constructive in-person meetings seemed to take a step back as the negotiating teams returned to their capitals.' Lutnick said China's restrictions on exports of critical minerals and magnets to the US would be resolved as a 'fundamental' part of the framework agreement. 'Also, there were a number of measures the United States of America put on when those rare earths were not coming,' Lutnick said. 'You should expect those to come off, sort of as President Trump said, in a balanced way.' Li said: 'Our communication has been very professional, rational, in-depth and candid.' Reuters and Agence France-Presse contributed to this report Sign in to access your portfolio

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store